Multisite Validation of a Strategy to Identify Very Low Risk Emergency Department Patients Without Troponin

Nicklaus P. Ashburn MD, MS , Anna C. Snavely PhD , Akalya Villenthi MS , Tara Hashemian MS , Michael W. Supples MD, MPH , Simon A. Mahler MD, MS
{"title":"Multisite Validation of a Strategy to Identify Very Low Risk Emergency Department Patients Without Troponin","authors":"Nicklaus P. Ashburn MD, MS ,&nbsp;Anna C. Snavely PhD ,&nbsp;Akalya Villenthi MS ,&nbsp;Tara Hashemian MS ,&nbsp;Michael W. Supples MD, MPH ,&nbsp;Simon A. Mahler MD, MS","doi":"10.1016/j.jacadv.2025.101913","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Patients with chest pain who are very low risk, defined by a History, Electrocardiogram, Age, and Risk factors (HEAR) score ≤1, may not require troponin testing.</div></div><div><h3>Objectives</h3><div>The aim of this study was to determine whether troponin testing is needed in patients with HEAR scores ≤1 in a multisite U.S. cohort.</div></div><div><h3>Methods</h3><div>We conducted an observational cohort study using the Wake Forest Chest Pain Registry. Patients ≥18 years old with HEART Pathway assessments and high-sensitivity troponin testing were accrued from 5 U.S. emergency departments (November 1, 2020-July 7, 2022). HEAR scores were prospectively completed by the treating clinician for patients with no known coronary artery disease and a nonischemic electrocardiogram. The outcome was 30-day major adverse cardiovascular events (MACE) (death, myocardial infarction [MI], and revascularization). The proportion of patients with HEAR scores ≤1 with MACE within 30 days was determined, and test characteristics were calculated. The net reclassification improvement index for troponin testing among patients with HEAR scores ≤1 was determined.</div></div><div><h3>Results</h3><div>Among 9,105 patients, 17.2% (1,565/9,105) had a HEAR score ≤1. At 30 days, MACE occurred in 0.7% (11/1,565; 95% CI: 0.4-1.3), with 3 deaths, 8 MIs, and 1 revascularization. The sensitivity and negative predictive value for 30-day MACE in patients with a HEAR score ≤1 were 97.9% (95% CI: 96.2-98.9) and 99.3% (95% CI: 98.7-99.6). Troponin testing correctly reclassified 8 with death, MI, or revascularization. Troponin was elevated among 74 without MACE, yielding a nonsignificant net reclassification improvement index of 0.7% (95% CI: −0.4 to 1.8).</div></div><div><h3>Conclusions</h3><div>Patients with no known coronary artery disease, a nonischemic electrocardiogram, and a HEAR score ≤1 had a missed MACE rate &lt;1%. Troponin testing identified additional patients with MACE but did not significantly improve risk stratification accuracy.</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 7","pages":"Article 101913"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC advances","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772963X25003333","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Patients with chest pain who are very low risk, defined by a History, Electrocardiogram, Age, and Risk factors (HEAR) score ≤1, may not require troponin testing.

Objectives

The aim of this study was to determine whether troponin testing is needed in patients with HEAR scores ≤1 in a multisite U.S. cohort.

Methods

We conducted an observational cohort study using the Wake Forest Chest Pain Registry. Patients ≥18 years old with HEART Pathway assessments and high-sensitivity troponin testing were accrued from 5 U.S. emergency departments (November 1, 2020-July 7, 2022). HEAR scores were prospectively completed by the treating clinician for patients with no known coronary artery disease and a nonischemic electrocardiogram. The outcome was 30-day major adverse cardiovascular events (MACE) (death, myocardial infarction [MI], and revascularization). The proportion of patients with HEAR scores ≤1 with MACE within 30 days was determined, and test characteristics were calculated. The net reclassification improvement index for troponin testing among patients with HEAR scores ≤1 was determined.

Results

Among 9,105 patients, 17.2% (1,565/9,105) had a HEAR score ≤1. At 30 days, MACE occurred in 0.7% (11/1,565; 95% CI: 0.4-1.3), with 3 deaths, 8 MIs, and 1 revascularization. The sensitivity and negative predictive value for 30-day MACE in patients with a HEAR score ≤1 were 97.9% (95% CI: 96.2-98.9) and 99.3% (95% CI: 98.7-99.6). Troponin testing correctly reclassified 8 with death, MI, or revascularization. Troponin was elevated among 74 without MACE, yielding a nonsignificant net reclassification improvement index of 0.7% (95% CI: −0.4 to 1.8).

Conclusions

Patients with no known coronary artery disease, a nonischemic electrocardiogram, and a HEAR score ≤1 had a missed MACE rate <1%. Troponin testing identified additional patients with MACE but did not significantly improve risk stratification accuracy.
一种识别无肌钙蛋白的极低风险急诊科患者策略的多地点验证
背景:胸痛的低危患者(病史、心电图、年龄和危险因素(HEAR)评分≤1)可能不需要肌钙蛋白检测。目的:本研究的目的是确定在美国多地点队列中,听力评分≤1的患者是否需要肌钙蛋白检测。方法:我们使用Wake Forest胸痛登记处进行了一项观察性队列研究。≥18岁接受HEART Pathway评估和高灵敏度肌钙蛋白检测的患者来自美国5个急诊科(2020年11月1日- 2022年7月7日)。对于没有已知冠状动脉疾病和非缺血性心电图的患者,由治疗临床医生前瞻性地完成HEAR评分。结果为30天主要不良心血管事件(MACE)(死亡、心肌梗死(MI)和血运重建术)。确定30天内HEAR评分≤1的患者发生MACE的比例,并计算试验特征。确定HEAR评分≤1的患者肌钙蛋白检测的净重分类改善指数。结果9105例患者中,17.2%(1565 / 9105)患者的HEAR评分≤1。30 d时,MACE发生率为0.7% (11/ 1565;95% CI: 0.4-1.3), 3例死亡,8例心肌梗死,1例血运重建术。对于HEAR评分≤1的患者,30天MACE的敏感性为97.9% (95% CI: 96.2-98.9),阴性预测值为99.3% (95% CI: 98.7-99.6)。肌钙蛋白检测正确地将其与死亡、心肌梗死或血运重建术重新分类。在没有MACE的74例患者中,肌钙蛋白升高,净重分类改善指数为0.7% (95% CI: - 0.4至1.8)。结论无已知冠状动脉疾病、非缺血性心电图、HEAR评分≤1的患者MACE漏报率为1%。肌钙蛋白检测发现了更多的MACE患者,但没有显著提高风险分层的准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JACC advances
JACC advances Cardiology and Cardiovascular Medicine
CiteScore
1.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信